期刊
THERANOSTICS
卷 13, 期 8, 页码 2616-2631出版社
IVYSPRING INT PUBL
DOI: 10.7150/thno.83920
关键词
Alternative splicing; Non-coding RNA; Cancer; Drug resistance; Chemotherapy; Targeted therapy; Immunotherapy
Alternative splicing is a common process in eukaryotic gene regulation, and it greatly enriches the complexity and diversity of mRNAs and proteins. Recent studies have found that non-coding RNAs (ncRNAs) are also involved in alternative splicing, and abnormal expression of ncRNAs and ncRNA-related splicing events are implicated in cancer initiation, progression, and drug resistance. Therefore, targeting ncRNAs, splicing factors, and splicing-related antigens may have therapeutic potential in cancer treatment.
Alternative splicing (AS) is a common and conserved process in eukaryotic gene regulation. It occurs in approximately 95% of multi-exon genes, greatly enriching the complexity and diversity of mRNAs and proteins. Recent studies have found that in addition to coding RNAs, non-coding RNAs (ncRNAs) are also inextricably linked with AS. Multiple different types of ncRNAs are generated by AS of precursor long non-coding (pre-lncRNAs) or precursor messenger RNAs (pre-mRNAs). Furthermore, ncRNAs, as a novel class of regulators, can participate in AS regulation by interacting with the cis-acting elements or trans-acting factors. Several studies have implicated abnormal expression of ncRNAs and ncRNA-related AS events in the initiation, progression, and therapy resistance in various types of cancers. Therefore, owing to their roles in mediating drug resistance, ncRNAs, AS-related factors and AS-related novel antigens may serve as promising therapeutic targets in cancer treatment. In this review, we summarize the interaction between ncRNAs and AS processes, emphasizing their great influences on cancer, especially on chemoresistance, and highlighting their potential values in clinical treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据